RCT: Tiragolumab plus atezolizumab vs. placebo plus atezolizumab as a first-line treatment for PD-L1-selected non-small-cell lung cancer.

Tiragolumab plus atezolizumab versus placebo plus atezolizumab as a first-line treatment for PD-L1-selected non-small-cell lung cancer (CITYSCAPE): primary and follow-up analyses of a randomised, double-blind, phase 2 study – The Lancet Oncology (link to abstract – $ for full-text)

Commentary: First-line tiragolumab–atezolizumab promising for PD-L1-positive advanced NSCLC – Medicine Matters